Title: “Sleep Apnea and Obesity: Management Issues”

Wednesday, December 17, 2025 at 8:00am-9:30am ET

Overview:

OSA affects up to 1 billion people worldwide with data suggesting prevalence figures which are increasing over time as a result of the obesity pandemic. Despite major progress in OSA management, many patients remain undiagnosed and untreated. Advances in pharmacology have led to improvements in obesity management. Tirzepatide has recently been FDA approved for the treatment of moderate to severe OSA in people with obesity. However, many questions remain regarding optimal management of OSA therapy including how best to mitigate cardiometabolic risk of these patients.  Many agents are in the pipeline for obesity pharmacology which have led to considerable excitement and discussion.

Learning Objectives:

  1. To understand the prevalence of obesity and OSA
  2. To review the SURMOUNT OSA results
  3. To consider future therapies for obesity and OSA

Panel:

Atul Malhotra, MD, FAASM (Chair)
Caroline M. Apovian, MD, FACP, FTOS, DABOM
Omavi Bailey, MD, MPH
Jeremy McConnell, MD, MFOMA, Dipl. ABOM

The webinar is made possible by the SRS Foundation and supported by Lilly.

Complimentary, Advanced Registration is Required.